Portland biotech firm ImmuCell completes $20 million expansion

Biotech firm ImmuCell Corp. of Portland has completed construction on a $20 million, pharmaceutical-grade factory that could help reduce the amount of antibiotics used in the dairy industry, Portland Press Herald reports.

The facility is designed to produce nisin, an antibacterial peptide that ImmuCell plans to sell in purified form as a natural alternative to antibiotics for treating a disease that afflicts lactating dairy cows.

If ImmuCell succeeds in obtaining U.S. Food and Drug Administration approval, the product would give it a competitive edge in the bovine health industry. Completing the production facility is a major step toward obtaining that approval.
Read full story
Immucell Press release Nov 2017

Related Posts

On the Record: Roux Institute’s Lars Perkins helps startups take off

Lars Perkins, a former software entrepreneur, Google executive and certified flight instructor who once flew planes for lifesaving “adventure philanthropy,” is managing...

28 November 2022

UNE to begin building new medical school at Portland campus

The University of New England is about to start a $93 million project to move the state’s only medical school from...

28 November 2022

Portland Planning Board recommends zoning changes for Roux Institute redevelopment

The Portland Planning Board is recommending that the city adopt zoning changes requested by the developers of a new graduate school...

22 November 2022